Veterinary Pain Management Market Forecast to 2030

Global Veterinary Pain Management market is projected to register a healthy CAGR of 6.44% during the reviewt period. Developing commonness of painful and fiery illnesses in creatures and ascend in sidekick creature proprietorship and huge pet populace are driving market development.

The ascent in sidekick creature possession and enormous animals' populace, ascend in pet protection with a flood in creature wellbeing consumption, and developing predominance of creature illnesses are supposed to drive the development of the worldwide veterinary pain management market.

The rising number of pet people across the globe is supposed to help market development over the forecast period. For example, as per the American Culture for the Anticipation of Mercilessness to Creatures (ASPCA), around 6.5 million sidekick creatures enter the US creature shields cross country every year. Besides, as expressed by the American Pet Items Affiliation 2015 to 2016 (APPA) study, roughly 44% of all families in the US had a canine, and 35% had a feline.

Market Segmentation

Devices and drugs are included in the product-based segmentation of the worldwide veterinary pain treatment market. The market has been further divided into categories based on pharmaceuticals, including opioids, local anesthetics, nonsteroidal anti-inflammatory drugs (NSAIDs), and others. The NSAIDs category has been further divided into categories such as etodolac, meloxicam, and others.

Joint pain, postoperative pain, cancer, and other conditions are among the applications used to segment the worldwide veterinary pain management market.

Companion and farm animals are the two animal types used to segment the worldwide veterinarian pain management market. Dogs, cats, horses, and other animals have been further subdivided under companion animals. The market has been further subdivided into cattle, pigs, poultry, and other livestock-based animals.

The global veterinary pain management market segmentation is based on a distribution channel that includes veterinary hospitals & clinics, pharmacies, and online pharmacies.

Regional Insights

The North America clear aligners market represented the biggest market share in 2022. This is because of the rising pet populace and the rising number of neurological sicknesses in the region. Besides, the presence of numerous observable players like Zoetis (New Jersey, US), Merck and Co., Inc. (New Jersey, US), and Assisi Creature Wellbeing (New Mexico, US) in this region is the significant driving variable of the market in the North America.

Europe Veterinary Pain Management market represents the second-largest market owing to the rising pervasiveness of contagious creature sicknesses and expanded center around the wellbeing and prosperity of creatures is driving the interest in pain management items.

The Asia-Pacific Veterinary Pain Management market expansion is attributed to the presence of quickly creating economies of China, India, and South Korea. The region gives numerous valuable chances to market players to develop. The expanded pet selections and development in the number of inhabitants in sidekick creatures is supposed to drive the market development.

The Middle East and Africa region has less monetary turns of events and very low pay because of which the region represents the least market share yet is supposed to develop with the to further developing veterinary medical care offices and extension of the working-class populace in these regions.

Major Players

Companies such as Boehringer Ingelheim (Ingelheim am Rhein, Germany), Vetoquinol (Lure, France), Ceva Animal Health, LLC (Libourne, France), Dechra Pharmaceuticals PLC (Northwich, UK), Zoetis (New Jersey, US), Merck & Co., Inc. (New Jersey, US), Assisi Animal Health(New Mexico, US), Eltech K-Laser (Treviso, Italy), Chanelle Pharma (Galway, Ireland), and Elanco (Indiana, US).

Product Code: MRFR/MED/4505-CR

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

1.1 OVERVIEW

2 MARKET INTRODUCTION

2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.4 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
- 3.6.1 BOTTOM-UP APPROACH
- 3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION

4 MARKET DYNAMICS

4.1 OVERVIEW
4.2 DRIVERS
- 4.2.1 GROWING PREVALENCE OF PAINFUL AND INFLAMMATORY DISEASES IN ANIMALS
- 4.2.2 RISE IN COMPANION ANIMAL OWNERSHIP & LARGE PET POPULATION
- 4.2.3 RISE IN PET INSURANCE WITH GROWING ANIMAL HEALTH EXPENDITURE
4.3 RESTRAINTS
- 4.3.1 LACK OF AWARENESS REGARDING ANIMAL HEALTH
- 4.3.2 UNAFFORDABILITY OF VETERINARY SERVICES IN UNDERDEVELOPED AND DEVELOPING REGIONS
4.4 OPPORTUNITIES
- 4.4.1 RISING INITIATIVES BY THE GOVERNMENT AND OTHER ORGANIZATIONS

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS
- 5.1.1 R&D & DESIGNING
- 5.1.2 MANUFACTURING
- 5.1.3 DISTRIBUTION & SALES
- 5.1.4 POST-SALES MONITORING
5.2 PORTER'S FIVE FORCES MODEL
- 5.2.1 THREAT OF NEW ENTRANTS
- 5.2.2 BARGAINING POWER OF SUPPLIERS
- 5.2.3 THREAT OF SUBSTITUTES
- 5.2.4 BARGAINING POWER OF BUYERS
- 5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE VETERINARY PAIN MANAGEMENT MARKET
- 5.3.1 IMPACT SUPPLY CHAIN DISRUPTIONS
- 5.3.2 IMPACT ON VETERINARY VISITS AND PROCEDURES
- 5.3.1 IMPACT ON ADAPTATION TO NEW PRACTICES AND TECHNOLOGIES

6 GLOBAL VETERINARY PAIN MANAGAMENT MARKET, BY PRODUCT

6.1 OVERVIEW
6.2 MEDICATION
- 6.2.1 NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)
  - 6.2.1.1.1 MELOXICAM
  - 6.2.1.2 ETODOLAC
  - 6.2.1.3 OTHERS
- 6.2.2 OPIOIDS
- 6.2.3 LOCAL ANESTHETICS
- 6.2.4 OTHERS
6.3 DEVICES
- 6.3.1 LASER THERAPY DEVICES
- 6.3.2 TENS UNITS

7 GLOBAL VETERINARY PAIN MANAGAMENT MARKET, BY APPLICATION

7.1 OVERVIEW
7.2 JOINT PAIN
7.3 POSTOPERATIVE PAIN
7.4 CANCER
7.5 OTHERS

8 GLOBAL VETERINARY PAIN MANAGAMENT MARKET, BY ANIMAL TYPE

8.1 OVERVIEW
8.2 COMPANION ANIMALS
- 8.2.1 DOGS
- 8.2.2 CATS
- 8.2.3 HORSES
- 8.2.4 OTHERS
8.3 LIVESTOCK ANIMALS
- 8.3.1 CATTLE
- 8.3.2 PIGS
- 8.3.3 POULTRY
- 8.3.4 OTHERS

9 GLOBAL VETERINARY PAIN MANAGAMENT MARKET, BY DISTRIBUTION CHANNEL

9.1 OVERVIEW
9.2 VETERINARY HOSPITALS & CLINICS
9.3 PHARMACIES
9.4 ONLINE PHARMACIES

10 GLOBAL VETERINARY PAIN MANAGEMENT MARKET, BY REGION

10.1 OVERVIEW
10.2 NORTH AMERICA
- 10.2.1 US
- 10.2.2 CANADA
10.3 EUROPE
- 10.3.1 GERMANY
- 10.3.2 UK
- 10.3.3 FRANCE
- 10.3.4 ITALY
- 10.3.5 SPAIN
- 10.3.6 REST OF EUROPE
10.4 ASIA-PACIFIC
- 10.4.1 CHINA
- 10.4.2 JAPAN
- 10.4.3 INDIA
- 10.4.4 SOUTH KOREA
- 10.4.5 AUSTRALIA
- 10.4.6 REST OF ASIA-PACIFIC
10.5 REST OF THE WORLD
- 10.5.1 LATIN AMERICA
- 10.5.2 MIDDLE EAST
- 10.5.3 AFRICA
11.1 OVERVIEW
11.2 COMPETITIVE BENCHMARKING
11.3 MAJOR GROWTH STRATEGY IN THE GLOBAL VETERINARY PAIN MANAGEMENT MARKET
11.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL VETERINARY PAIN MANAGEMENT MARKET
11.5 KEY DEVELOPMENT ANALYSIS
11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 11.6.1 PRODUCT APPROVAL AND LAUNCH
- 11.6.2 EXPANSION
- 11.6.3 ACQUISITION
11.7 FINANCIAL MATRIX
- 11.7.1 SALES (USD MILLION), 2022
- 11.7.2 RESEARCH & DEVELOPMENT EXPENDITURE (USD MILLION), 2022

12 COMPANY PROFILES

12.1 BOEHRINGER INGELHEIM
- 12.1.1 COMPANY OVERVIEW
- 12.1.2 FINANCIAL OVERVIEW
- 12.1.3 PRODUCTS OFFERED
- 12.1.4 KEY DEVELOPMENTS
- 12.1.5 SWOT ANALYSIS
- 12.1.6 KEY STRATEGIES
12.2 VETOQUINOL
- 12.2.1 COMPANY OVERVIEW
- 12.2.2 FINANCIAL OVERVIEW
- 12.2.3 PRODUCTS OFFERED
- 12.2.4 KEY DEVELOPMENTS
- 12.2.5 SWOT ANALYSIS
- 12.2.6 KEY STRATEGIES
12.3 CEVA ANIMAL HEALTH, LLC
- 12.3.1 COMPANY OVERVIEWS
- 12.3.2 FINANCIAL OVERVIEW
- 12.3.3 PRODUCTS OFFERED
- 12.3.4 KEY DEVELOPMENTS
- 12.3.5 KEY STRATEGIES
12.4 CHANELLE PHARMA
- 12.4.1 COMPANY OVERVIEW
- 12.4.2 FINANCIAL OVERVIEW
- 12.4.3 PRODUCTS OFFERED
- 12.4.4 KEY DEVELOPMENTS
- 12.4.5 KEY STRATEGIES
12.5 ELANCO
- 12.5.1 COMPANY OVERVIEW
- 12.5.2 FINANCIAL OVERVIEW
- 12.5.3 PRODUCTS OFFERED
- 12.5.4 KEY DEVELOPMENTS
- 12.5.5 SWOT ANALYSIS
- 12.5.6 KEY STRATEGIES
12.6 DECHRA PHARMACEUTICALS PLC
- 12.6.1 COMPANY OVERVIEWS
- 12.6.2 FINANCIAL OVERVIEW
- 12.6.3 PRODUCTS OFFERED
- 12.6.4 KEY DEVELOPMENTS
- 12.6.5 KEY STRATEGIES
12.7 ZOETIS
- 12.7.1 COMPANY OVERVIEW
- 12.7.2 FINANCIAL OVERVIEW
- 12.7.3 PRODUCTS OFFERED
- 12.7.4 KEY DEVELOPMENTS
- 12.7.5 SWOT ANALYSIS
- 12.7.6 KEY STRATEGIES
12.8 MERCK & CO., INC
- 12.8.1 COMPANY OVERVIEW
- 12.8.2 FINANCIAL OVERVIEW
- 12.8.3 PRODUCTS OFFERED
- 12.8.4 KEY DEVELOPMENTS
- 12.8.5 SWOT ANALYSIS
- 12.8.6 KEY STRATEGIES
12.9 ASSISI ANIMAL HEALTH
- 12.9.1 COMPANY OVERVIEW
- 12.9.2 FINANCIAL OVERVIEW
- 12.9.3 PRODUCTS OFFERED
- 12.9.4 KEY DEVELOPMENTS
- 12.9.5 KEY STRATEGIES
12.10 ELTECH K-LASER
- 12.10.1 COMPANY OVERVIEW
- 12.10.2 FINANCIAL OVERVIEW
- 12.10.3 PRODUCTS OFFERED
- 12.10.4 KEY DEVELOPMENTS
- 12.10.5 KEY STRATEGIES

13 APPENDIX

13.1 REFERENCES
13.2 RELATED REPORTS